Drug Profile
NE 3107
Alternative Names: 17α-ethynyl-5-androstene-3β,7β,17β-triol; 3α-ethynyl-androst-5-ene-3β,7β,17β-triol; HE 3286; NE-3107; Triolex®Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Hollis-Eden Pharmaceuticals
- Developer BioVie; Harbor Therapeutics; National Institutes of Health (USA); NeurMedix
- Class Anti-inflammatories; Antidementias; Antiepileptic drugs; Antifibrotics; Antiglaucomas; Antihyperglycaemics; Antimigraines; Antineoplastics; Antiparkinsonians; Antirheumatics; Hormones; Insulin sensitisers; Nootropics; Obesity therapies; Small molecules
- Mechanism of Action Interleukin 23 inhibitors; Interleukin 6 inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cystic fibrosis
Highest Development Phases
- Phase III Alzheimer's disease
- Phase II Parkinson's disease
- Preclinical Multiple myeloma; Prostate cancer
- No development reported Drug-induced dyskinesia
- Discontinued Amyotrophic lateral sclerosis; Cognition disorders; Cystic fibrosis; Epilepsy; Glaucoma; Huntington's disease; Migraine; Myositis; Optic neuritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Ulcerative colitis; Uveitis
Most Recent Events
- 11 Mar 2024 BioVie plans a phase IIb trial for Parkinson's disease (Monotherapay, Treatment-naive) in the late summer of 2024
- 01 Mar 2024 Efficacy data from a phase III trial in Alzheimer's disease released by BioVie
- 01 Mar 2024 Efficacy data from a phase II NM201 trial in Parkinson's disease released by BioVie